Moleculin Biotech Inc
MBRX
Company Profile
Business description
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company’s Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
Contact
5300 Memorial Drive
Suite 950
HoustonTX77007
USAT: +1 713 300-5160
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
17
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,757.90 | 13.20 | -0.15% |
| CAC 40 | 7,643.67 | 40.06 | -0.52% |
| DAX 40 | 23,265.71 | 168.94 | -0.72% |
| Dow JONES (US) | 42,226.46 | 10.66 | 0.03% |
| FTSE 100 | 8,841.56 | 7.53 | 0.09% |
| HKSE | 23,710.69 | 269.61 | -1.12% |
| NASDAQ | 19,499.80 | 21.29 | -0.11% |
| Nikkei 225 | 38,885.15 | 348.41 | 0.90% |
| NZX 50 Index | 12,627.32 | 12.03 | -0.10% |
| S&P 500 | 5,982.67 | 0.05 | -0.00% |
| S&P/ASX 200 | 8,531.20 | 10.10 | -0.12% |
| SSE Composite Index | 3,388.81 | 1.40 | 0.04% |